sellWeak cluster of 3
Benjamin Halladay sold $7,866 of ESPR
Chief Financial Officer at Esperion Therapeutics, Inc.. 3,245 shares at an average of $2.42, traded Dec 17, 2024, filed Dec 18, 2024.
Warning score
37Value
$7,866
3,245 shares
Holdings after
240,691
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$8k at market
- 0Share of holdings soldSold 1.3% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-24-051875, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | SOpen-market sale Common Stock | -3,245 | $2.42 | $7,866 | 240,691 | Dec 18, 2024 |
Related signals
Other insiders at Esperion Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $24k 6,517 shares | -2% | |
| 42Moderate | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $27k 7,337 shares | -2% | |
| 52Moderate | Esperion Therapeutics, Inc. | Sheldon L. Koenig President and CEO | $177k 48,244 shares | -3% | |
| 15Weak | ESPRsell Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $3,275 1,248 shares | -0% | |
| 49Moderate | Esperion Therapeutics, Inc. | Sheldon L. Koenig President and CEO | $79k 28,427 shares | -2% | |
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $18k 6,267 shares | -2% | |
| 37Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $20k 7,046 shares | -1% | |
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $12 11 shares | -0% | |
| 23Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $1,470 1,304 shares | -0% | |
| 37Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $8,328 7,229 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.